These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30242996)

  • 1. Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Systemic Lupus Erythematosus Patients.
    Zaitoon YA; Shehab AA; Mohamed NA; Morad CS; Yassine EM
    Egypt J Immunol; 2018 Jan; 25(1):35-43. PubMed ID: 30242996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.
    Toldi G; Szalay B; Bekő G; Bocskai M; Deák M; Kovács L; Vásárhelyi B; Balog A
    Biomarkers; 2012 Dec; 17(8):758-63. PubMed ID: 23033975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity.
    Burcsár S; Toldi G; Kovács L; Szalay B; Vásárhelyi B; Balog A
    Biomarkers; 2021 Jul; 26(5):443-449. PubMed ID: 33825610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase plasminogen activator receptor--a valuable biomarker in systemic lupus erythematosus?
    Enocsson H; Sjöwall C; Wetterö J
    Clin Chim Acta; 2015 Apr; 444():234-41. PubMed ID: 25704300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission.
    Toldi G; Bekő G; Kádár G; Mácsai E; Kovács L; Vásárhelyi B; Balog A
    Clin Chem Lab Med; 2013 Feb; 51(2):327-32. PubMed ID: 22718576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.
    Enocsson H; Wirestam L; Dahle C; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma AA; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; van Vollenhoven RF; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken CA; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C
    J Autoimmun; 2020 Jan; 106():102340. PubMed ID: 31629628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
    Xiao Y; Luo H; Zhou B; Dai X; Huang J; Duan L; You Y; Zhang W; Zhao H; Xie Y; Zhou Y; Ning W; Li T; Liu S; Zhu H; Xie X; Jiang Y; Wu S; He W; Li Y
    Rheumatol Int; 2017 Apr; 37(4):585-592. PubMed ID: 27878344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.
    Scharrenberg JS; Yagdiran A; Brinkmann J; Brune M; Siewe J; Jung N; Mahabir E
    J Orthop Surg Res; 2019 Nov; 14(1):367. PubMed ID: 31727136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis.
    Toldi G; Szalay B; Bekő G; Kovács L; Vásárhelyi B; Balog A
    Joint Bone Spine; 2013 Jan; 80(1):96-8. PubMed ID: 22999906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
    Kaya S; Köksal I; Menteşe A; Sönmez M; Sümer A; Yıldırım SS; Yılmaz G
    Int J Infect Dis; 2013 Nov; 17(11):e1056-9. PubMed ID: 23742830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders.
    Vasarhelyi B; Toldi G; Balog A
    EJIFCC; 2016 Apr; 27(2):122-9. PubMed ID: 27683525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China.
    Qin DD; Song D; Huang J; Yu F; Zhao MH
    Lupus; 2015 May; 24(6):546-57. PubMed ID: 25411257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis.
    Okulu E; Arsan S; Akin IM; Ates C; Alan S; Kilic A; Atasay B
    J Clin Lab Anal; 2015 Sep; 29(5):347-52. PubMed ID: 25043869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity.
    Saylam Kurtipek G; Kesli R; Tuncez Akyurek F; Akyurek F; Ataseven A; Terzi Y
    Int J Rheum Dis; 2018 Apr; 21(4):866-870. PubMed ID: 27171829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-γ, CXCL16, uPAR: potential biomarkers for systemic lupus erythematosus.
    Wen S; He F; Zhu X; Yuan S; Liu H; Sun L
    Clin Exp Rheumatol; 2018; 36(1):36-43. PubMed ID: 28628472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
    Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
    Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity.
    Kurtipek GS; Kesli R; Tunçez Akyürek F; Akyüret F; Terzi Y
    Acta Dermatovenerol Alp Pannonica Adriat; 2015; 24(4):73-5. PubMed ID: 26697731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia.
    Toldi G; Bíró E; Szalay B; Stenczer B; Molvarec A; Rigó J; Vásárhelyi B; Bekõ G
    Clin Chem Lab Med; 2011 Nov; 49(11):1873-6. PubMed ID: 21722073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.